Global opportunity

Back the breakthrough.
Redefine treatment. With us.

Antigenika sits at the intersection of high unmet clinical need, strong scientific innovation and scalable global impact.

The size of the prize

A neglected market, ready for innovation

Snakebite envenoming is one of the most overlooked yet devastating medical emergencies of our time. Antivenom has barely changed in over a century, leaving millions of patients without timely or adequate care.

0M

Snakebites annually

0M

Serious envenomings annually

0K

Deaths per year

0K

Life-changing disabilities

Sources: WHO, eLife, Nature Comms, PLOS NTD.

Why now, why us

Six reasons to back Antigenika

Each pillar reinforces the next: a large unmet need, a differentiated approach, a credible foundation, a clear regulatory path, a scalable platform, and global alignment behind us.

Snakebite envenoming affects millions every year, yet treatment innovation has been limited for decades.

Global impact

5.4 million bites and 2.7 million serious envenomings each year, with venomous species present in more than 90% of countries globally.

WHO recognition

Recognised by the WHO as a priority neglected tropical disease with dedicated 2030 targets to halve the global burden.

Market opportunity

A multi-billion dollar addressable market with virtually no innovation since the 1890s, creating unprecedented first-mover advantages.

The first meaningful breakthrough in more than a century. Our oral combination therapy is designed to enable early intervention at the point of need, addressing the critical limitations of antivenom-based care.

Field-ready delivery

Oral, heat-stable format with no IV or cold-chain dependency, enabling immediate treatment in remote areas where 80% of bites occur.

Broad-spectrum protection

Multi-pathway inhibition designed to work across medically significant species, solving the species-identification problem that limits antivenom effectiveness.

Tissue preservation

Our approach targets tissue-destroying enzymes like metalloproteases and phospholipase A2, designed to prevent the lifelong disabilities that antivenom cannot address. We protect both life and limb.

Built on research from the University of Reading and led by internationally recognised venom pharmacologists, with an expanding evidence base behind the lead programme.

Proven mechanism

Robust mechanistic rationale targeting the most conserved and destructive pathways across snake venoms, validated through years of academic research.

Extensive validation

Preclinical validation across 15+ venoms covering the major medically significant species responsible for global snakebite burden.

Clinical pathway

Clear regulatory strategy with accelerated clinical pathway opportunities due to the critical unmet medical need and orphan drug potential.

A defined regulatory strategy with strategic groundwork already underway in our priority launch regions, designed for rapid market penetration.

Regulatory strategy

Defined regulatory pathway including accelerated approval opportunities through orphan drug designation and priority review mechanisms.

India partnership

Strategic partnership in India supporting early market entry in the world's largest snakebite burden country, with established distribution channels.

Global rollout

Tiered expansion strategy designed to scale through LMICs where the burden is highest, then into high-income markets with premium pricing.

Designed from day one for global deployment, with manufacturing economics that support reach into the regions most affected.

Manufacturing advantage

Low-cost, scalable small-molecule manufacturing enables affordable pricing for LMIC markets while maintaining strong margins in developed markets.

Platform expansion

Pipeline expansion into veterinary markets and adjacent toxin-related indications, creating multiple revenue streams from the same core technology.

IP position

Strong intellectual property portfolio around novel combinations and applications, with freedom to operate in key global markets.

Snakebite is a recognised priority neglected tropical disease. Our work sits squarely within an expanding global health agenda.

WHO 2030 targets

Aligned with WHO 2030 targets to halve the global burden, with increasing government and NGO funding committed to snakebite solutions.

Policy momentum

Growing policy focus through national snakebite strategies, particularly in high-burden countries like India, Nigeria, and Brazil.

ESG appeal

Strong ESG credentials addressing health equity, with measurable impact metrics that appeal to impact investors and development finance.

Beyond therapeutics

A commitment to global impact

Antigenika’s mission extends beyond therapeutic innovation. Our progress is designed to deliver broader value alongside improved patient outcomes.

We support partnerships with organisations working on the ground in emerging economies — enabling sustainable livelihoods and advancing environmental initiatives, including tree-planting programmes that directly benefit local communities.

A portion of company proceeds supports initiatives in health, education and sustainability, ensuring our progress delivers broader global impact.

Talk to us

Partners and investors

For deeper technical, regulatory or commercial detail, we share briefings directly with partners and investors under confidentiality.

Request a briefing See the pipeline